Lead identification using 3D models of pancreatic cancer

Recent technological advances have enabled 3D tissue culture models for fast and affordable HTS. We are no longer bound to 2D models for anti-cancer agent discovery, and it is clear that 3D tumor models provide more predictive data for translation of preclinical studies. In a previous study, we vali...

Full description

Saved in:
Bibliographic Details
Published in:SLAS discovery 2022-04, Vol.27 (3), p.159-166
Main Authors: Fernandez-Vega, Virneliz, Hou, Shurong, Plenker, Dennis, Tiriac, Hervé, Baillargeon, Pierre, Shumate, Justin, Scampavia, Louis, Seldin, Jan, Souza, Glauco R., Tuveson, David A., Spicer, Timothy P.
Format: Article
Language:English
Subjects:
Cell Proliferation
HTS
Humans
Magnetic bioprinting
Organoid
Organoids
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Phenotypic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent technological advances have enabled 3D tissue culture models for fast and affordable HTS. We are no longer bound to 2D models for anti-cancer agent discovery, and it is clear that 3D tumor models provide more predictive data for translation of preclinical studies. In a previous study, we validated a microplate 3D spheroid-based technology for its compatibility with HTS automation. Small-scale screens using approved drugs have demonstrated that drug responses tend to differ between 2D and 3D cancer cell proliferation models. Here, we applied this 3D technology to the first ever large-scale screening effort completing HTS on over 150K molecules against primary pancreatic cancer cells. It is the first demonstration that a screening campaign of this magnitude using clinically relevant, ex-vivo 3D pancreatic tumor models established directly from biopsy, can be readily achieved in a fashion like traditional drug screen using 2D cell models. We identified four unique series of compounds with sub micromolar and even low nanomolar potency against a panel of patient derived pancreatic organoids. We also applied the 3D technology to test lead efficacy in autologous cancer associated fibroblasts and found a favorable profile for better efficacy in the cancer over wild type primary cells, an important milestone towards better leads. Importantly, the initial leads have been further validated in across multiple institutes with concordant outcomes. The work presented here represents the genesis of new small molecule leads found using 3D models of primary pancreas tumor cells.
ISSN:2472-5552
2472-5560
DOI:10.1016/j.slasd.2022.03.002